Rise Advisors, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.

Quarter-by-quarter ownership
Rise Advisors, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$2,284
-18.9%
830.0%0.00%0.0%
Q2 2023$2,816
-5.7%
830.0%0.00%0.0%
Q1 2023$2,986
-19.3%
830.0%0.00%
-33.3%
Q4 2022$3,699
+85.0%
830.0%0.00%
+50.0%
Q3 2022$2,0000.0%830.0%0.00%0.0%
Q2 2022$2,000
-33.3%
830.0%0.00%
-33.3%
Q1 2022$3,000
-99.9%
830.0%0.00%0.0%
Q4 2021$3,207,000830.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders